Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation

Tamsulosin OCAS 0.4 mg demonstrates a lower incidence of positive orthostatic tests following single dosing in fasting healthy elderly subjects compared to tamsulosin MR 0.4 mg. This is probably related to the improved controlled release characteristics (lower Cmax) of the OCAS formulation. It indicates that on an empty stomach tamsulosin OCAS provides a better cardiovascular safety profile than tamsulosin MR.